eXoZymes Inc. (EXOZ)
EXOZ moved a median of -0.17% 30 minutes after news, and -1.38% by the close. How EXOZ actually reacts to news — the realized, point-in-time move the market made, measured across 78 labeled events over the last three years with zero look-ahead.
EXOZ’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 20% | 45 |
| 30-min | -0.17% | 31% | 61 |
| 60-min | -1.76% | 31% | 67 |
| to close | -1.38% | 32% | 75 |
| Middle 50% of EXOZ reactions | -4.92% to +0.97% |
|---|---|
| Median reaction (30-min) | -0.17% |
| Measured reactions | 78 |
Half of all eXoZymes Inc. news events land between -4.92% and +0.97% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when EXOZ moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to EXOZ's baseline. Nothing else.
Recent EXOZ events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K EXOZYMES INC. For: Oct 09 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.59% | |
| Form DEF 14A EXOZYMES INC. For: Nov 13 | SEC filing · Form DEF | SEC EDGAR | — | +3.56% | |
| Form DEFA14A EXOZYMES INC. | SEC filing · Form DEFA14A | SEC EDGAR | — | +3.56% | |
| Form 8-K EXOZYMES INC. For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | — | +0.70% | |
| eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT | Press release | ACCESS Newswire | -4.17% | -12.36% | |
| eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today | Press release | ACCESS Newswire | -0.69% | -1.38% | |
| eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets | Press release | ACCESS Newswire | -6.89% | -1.99% | |
| Form 10-Q EXOZYMES INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | +0.00% | |
| eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026 | Press release | ACCESS Newswire | +0.00% | -4.00% | |
| eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing | Press release | ACCESS Newswire | — | -0.84% | |
| Form 8-K EXOZYMES INC. For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | — | +6.80% | |
| Q2 Virtual Investor Summit Presentations Now Available On Demand | Press release | ACCESS Newswire | — | +0.00% | |
| Form 8-K EXOZYMES INC. For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | +2.57% | +5.80% | |
| eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery | Press release | ACCESS Newswire | +1.84% | +4.96% | |
| eXoZymes Inc. Announces Closing of $6 Million Public Offering | Press release | ACCESS Newswire | — | +20.46% | |
| Form 8-K EXOZYMES INC. For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | — | +20.46% | |
| eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants | Press release | ACCESS Newswire | +5.44% | -4.22% | |
| eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program | Press release | ACCESS Newswire | — | -7.41% | |
| eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast | Press release | ACCESS Newswire | -4.68% | -0.43% | |
| Form 8-K EXOZYMES INC. For: Apr 10 | SEC filing · Form 8-K | SEC EDGAR | — | +0.00% | |
| eXoZymes Provides Fourth Quarter and Full Year 2025 Update | Press release | ACCESS Newswire | +0.13% | +5.63% | |
| Form 8-K EXOZYMES INC. For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | +0.67% | +0.13% | |
| Form 10-K EXOZYMES INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.67% | +0.13% | |
| eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026 | Press release | ACCESS Newswire | +0.00% | -0.96% | |
| Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability | Press release | ACCESS Newswire | -1.75% | -4.04% | |
| eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium | Press release | ACCESS Newswire | +0.00% | +0.14% | |
| With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation | Press release | ACCESS Newswire | +0.00% | -2.91% | |
| Form 8-K EXOZYMES INC. For: Jan 29 | SEC filing · Form 8-K | SEC EDGAR | -1.76% | -4.74% | |
| eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run | Press release | ACCESS Newswire | — | +2.16% | |
| Form EFFECT EXOZYMES INC. | SEC filing · Form EFFECT | SEC EDGAR | — | -0.17% | |
| Form S-3 EXOZYMES INC. | SEC filing · Form S-3 | SEC EDGAR | — | -8.61% | |
| Form S-8 EXOZYMES INC. | SEC filing · Form S-8 | SEC EDGAR | — | -7.26% | |
| Form 8-K EXOZYMES INC. For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -8.95% | |
| eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion | Press release | ACCESS Newswire | +0.00% | -8.95% | |
| eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST | Press release | ACCESS Newswire | — | -5.01% | |
| CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference | Press release | ACCESS Newswire | — | -3.36% | |
| CEO of eXoZymes to Present at Spartan Capital Securities' Second Annual Investor Conference | Press release | ACCESS Newswire | — | — | |
| CEO of eXoZymes to Present at ThinkEquity's Annual Investor Conference | Press release | ACCESS Newswire | — | -2.56% | |
| Form 8-K EXOZYMES INC. For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | — | +4.07% | |
| Driving the Cell-Free Revolution: eXoZymes Leaders Join BioMADE Leadership & Technical Committees | Press release | ACCESS Newswire | — | +3.47% | |
| eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today | Press release | ACCESS Newswire | +0.00% | +2.46% | |
| Form 10-Q EXOZYMES INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +2.46% | |
| eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST | Press release | ACCESS Newswire | — | -1.90% | |
| eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity | Press release | ACCESS Newswire | +1.10% | — | |
| Form 8-K EXOZYMES INC. For: Jul 25 | SEC filing · Form 8-K | SEC EDGAR | -1.27% | -2.70% | |
| eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months | Press release | ACCESS Newswire | — | +1.28% | |
| Form 8-K EXOZYMES INC. For: Jul 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.19% | |
| eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing | Press release | ACCESS Newswire | +0.00% | -3.62% | |
| Form 8-K EXOZYMES INC. For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.62% | |
| Form DEFR14A EXOZYMES INC. | SEC filing · Form DEFR14A | SEC EDGAR | — | -1.90% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the EXOZ section they belong to.
Where else EXOZ is measured.
EXOZ earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is eXoZymes Inc.'s median reaction calculated?
Every labeled EXOZ news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 78 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 31% of EXOZ's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does EXOZ's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.